Lion Street Advisors LLC Buys 5,619 Shares of Axsome Therapeutics, Inc. $AXSM
Lion Street Advisors LLC increased its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 62.0% in the third quarter, acquiring an additional 5,619 shares. This brings their total holdings to 14,677 shares valued at $1,783,000. Other institutional investors have also adjusted their positions, and analysts currently rate AXSM a "Moderate Buy" with an average price target of $216.07.
Axsome Therapeutics Q4 2025 earnings preview
This article provides a preview of Axsome Therapeutics' Q4 2025 earnings report. Main topics expected to be covered include financial performance for the quarter, updates on drug development, and future outlook for the company.
Axsome earnings on deck as Alzheimer’s agitation decision looms
Axsome Therapeutics Inc. is set to release its Q4 and full-year 2025 earnings, with analysts anticipating a loss of $0.73 per share on $189.8 million revenue, driven by strong sales of Auvelity and other drugs. This report comes as the company awaits a critical FDA decision on AXS-05 for Alzheimer's disease agitation by April 30, 2026, a potential blockbuster opportunity. Investors will focus on Auvelity's sustained growth, the company's path to profitability, and its late-stage pipeline including expanded indications and new development programs.
Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards?
Collegium Pharmaceutical (COLL) is set to announce its Q4 and full-year 2025 results on February 26, with analysts forecasting revenues of $208.6 million and earnings of $2.19 per share. The company's performance is expected to be driven by its ADHD drug Jornay PM and its pain management portfolio, which saw record revenues in the previous quarter. Despite a strong historical earnings surprise record, the Zacks Earnings ESP model does not predict an earnings beat for COLL this quarter, indicating a potential miss.
Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Axsome Therapeutics, Inc. announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference, where it will present on Wednesday, February 25, 2026, at 2:00 p.m. ET. A webcast of the presentation will be available on the company's website. Axsome Therapeutics is a biopharmaceutical company focused on developing treatments for central nervous system disorders.
How to watch Axsome Oppenheimer healthcare conference talk live
Axsome Therapeutics (NASDAQ: AXSM) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026, at 2:00 p.m. ET. A live webcast will be available on the company's investor relations page, and a replay will be accessible for approximately 30 days afterward. This presentation is a standard investor conference appearance and is not expected to include financial results or new clinical data not previously announced.
Axsome SUNOSI Patent Settlement Clarifies Exclusivity Window And Future Competition
Axsome Therapeutics has settled patent litigation with Alkem Laboratories regarding its drug SUNOSI, establishing a potential generic entry date of 2040, subject to regulatory review. This agreement provides clarity on SUNOSI's exclusivity window, removing a legal overhang and allowing Axsome to better plan its product lifecycle. While an ongoing legal challenge with another party remains, the settlement strengthens Axsome's intellectual property position and offers investors a clearer timeline for future competition.
AXSM Stock Price, Forecast & Analysis | AXSOME THERAPEUTICS INC (NASDAQ:AXSM)
This article provides a detailed analysis of AXSOME THERAPEUTICS INC (NASDAQ:AXSM), including its current stock price, key statistics, technical and fundamental ratings, financial highlights, and analyst forecasts. ChartMill rates AXSM with a technical score of 9/10 and a fundamental score of 2/10, noting concerns about profitability and health. Analysts project an average price target of $217.31, suggesting a 16.73% increase, with expected EPS growth of 36.83% and revenue growth of 64.9% for the next year.
Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?
Recursion Pharmaceuticals (RXRX) is set to report its fourth-quarter 2025 earnings, with Zacks Consensus Estimates projecting a loss of 28 cents per share on revenues of $25.5 million. The TechBio company relies on collaboration and grant revenues and will likely provide updates on its clinical-stage pipeline, including lead candidate REC-4881 and other early-stage programs. Despite a mixed earnings surprise history and a Zacks Rank #2, the article also highlights other drug/biotech stocks like Castle Biosciences (CSTL), Immunovant (IMVT), and Axsome Therapeutics (AXSM) with potential for earnings beats.
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
Axsome Therapeutics has settled a patent litigation with Alkem Laboratories Ltd. regarding Axsome's product SUNOSI® (solriamfetol). The settlement grants Alkem a license to sell a generic version of SUNOSI starting in 2040, subject to pediatric exclusivity and FDA approval. A similar litigation against another party remains pending.
Axsome secures long-term SUNOSI exclusivity through Alkem settlement
Axsome Therapeutics has reached a settlement agreement with Alkem Laboratories, resolving a patent lawsuit over its drug SUNOSI. The agreement grants Alkem a license to sell a generic version of SUNOSI starting in 2040, securing long-term market exclusivity for Axsome's product. This settlement is subject to regulatory review and ongoing related litigation, and despite strong gross margins and revenue growth, Axsome's financial quality is restrained by ongoing losses, negative cash flow, and high leverage.
Axsome, Alkem strike deal setting 2040 start for U.S. SUNOSI generic
Axsome Therapeutics has settled patent litigation with Alkem Laboratories regarding its product SUNOSI (solriamfetol). The agreement allows Alkem to market a generic version of SUNOSI starting March 1, 2040, or September 1, 2040, if pediatric exclusivity is granted, contingent on FDA approval. This settlement is subject to review by the U.S. Federal Trade Commission and Department of Justice, and separate litigation with another party over SUNOSI remains ongoing.
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
Axsome Therapeutics has reached a settlement agreement with Alkem Laboratories Ltd. regarding patent litigation concerning Axsome's product SUNOSI® (solriamfetol). The agreement grants Alkem a license to sell a generic version of SUNOSI starting on or after September 1, 2040, or March 1, 2040, depending on pediatric exclusivity. This settlement resolves one instance of patent litigation, while a similar case against another party remains pending.
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Should You Buy?
Axsome Therapeutics (AXSM) is projected to surpass its earnings estimates for the quarter ending December 2025, with an expected year-over-year increase in earnings and 62.5% higher revenues. The company's Zacks Earnings ESP of +30.00% combined with a Zacks Rank #3 suggests a strong likelihood of an earnings beat. Investors are advised to consider these factors, along with other financial indicators, before making investment decisions.
Axsome Therapeutics (AXSM) Expected to Announce Quarterly Earnings on Monday
Axsome Therapeutics (AXSM) is projected to announce its Q4 2025 earnings before market open on Monday, February 23rd, with analysts expecting a loss of ($0.72) EPS on $191.33 million in revenue. The stock has a "Moderate Buy" consensus rating and a target price of $210.65, despite recent significant insider selling totaling over $51 million. Institutional investors have slightly increased their positions, while the company's stock currently trades around $181.21.
Axsome initiated with Overweight at Wells Fargo on Alzheimer's drug potential
Wells Fargo has initiated coverage on Axsome Therapeutics with an Overweight rating, citing the significant potential of its Alzheimer's drug. The firm projects the drug could achieve blockbuster sales, driven by strong efficacy and a large market opportunity.
Why (AXSM) Price Action Is Critical for Tactical Trading
Axsome Therapeutics Inc. (NASDAQ: AXSM) is showing a neutral sentiment in the near and mid-term, with a potential breakout underway, while long-term support signals are diminishing. The article outlines three AI-generated trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, complete with entry zones, targets, and stop losses. Multi-timeframe analysis also indicates strong long-term signals despite the neutral short-to-mid-term outlook.
Morgan Stanley Remains Bullish on Axsome (AXSM), Reiterates $190 PT
Morgan Stanley has reiterated its Overweight rating and $190 price target for Axsome Therapeutics (AXSM). This continued bullish stance suggests confidence in the pharmaceutical company's future performance and valuation. The reaffirmation of the price target indicates that the firm sees significant upside potential for Axsome's stock.
Auvelity Priority Review And Revenue Update Could Be A Game Changer For Axsome Therapeutics (AXSM)
Axsome Therapeutics' lead drug, Auvelity, has received priority FDA review for treating agitation in Alzheimer's disease, with a target action date of April 30, 2026. This, alongside strong interim unaudited 2025 revenue growth, signals potential for significant long-term expansion in the company's commercial footprint and pipeline. While optimism is already reflected in the stock, investors should consider risks like continued losses and execution challenges.
Auvelity Priority Review And Revenue Update Could Be A Game Changer For Axsome Therapeutics (AXSM)
Axsome Therapeutics has seen strong product revenue growth in unaudited 2025 results and its lead drug, Auvelity, received priority FDA review for agitation in Alzheimer’s disease with a target action date of April 30, 2026. These developments suggest a potential reshaping of the company's long-term revenue mix through commercial expansion and pipeline advancements in CNS disorders. Despite recent stock appreciation, the company still faces risks related to ongoing losses, execution of multiple launches, and high expectations.
Auvelity Priority Review And Revenue Update Could Be A Game Changer For Axsome Therapeutics (AXSM)
Axsome Therapeutics has reported strong interim unaudited 2025 revenue growth and secured priority FDA review for its drug Auvelity for Alzheimer’s agitation, with a target action date of April 30, 2026. These developments highlight the company's expanding commercial footprint and late-stage pipeline in CNS disorders, which could significantly impact its long-term revenue mix. While the stock has seen considerable optimism, investors should also consider the risks associated with continued losses and debt.
Axsome Therapeutics Stock Soars 75% Amid Strong Growth
Axsome Therapeutics (AXSM) stock has surged 75% over the past year, significantly outperforming the S&P 500, driven by impressive Q3 2025 earnings and the priority review status for its Alzheimer's drug AXS-05. Despite a robust market cap and revenue growth, the company remains unprofitable with a high price-to-sales ratio, prompting caution for investors who must weigh the considerable influence of regulatory news on its stock performance. Analysts project continued growth, with several firms raising price targets due to strong product sales and anticipated FDA approvals.
Axsome Therapeutics (AXSM) Valuation After FDA Review Focus And Strong CNS Growth Momentum
Axsome Therapeutics (AXSM) is gaining attention due to an FDA review of Auvelity for Alzheimer’s disease agitation, strong revenue growth, and positive analyst sentiment for its CNS franchise. While simply Wall St’s narrative suggests the stock is 10.9% undervalued with a fair value of $210.19, driven by high revenue growth and improving margins, another market multiple view indicates the stock's current P/S ratio is higher than its fair ratio and the industry average. Investors should consider the risks associated with heavy reliance on Auvelity and Sunosi, alongside ongoing net losses and cash burn.
1 High-Flying Stock With More Upside Ahead
Axsome Therapeutics (NASDAQ: AXSM) has seen significant growth due to its current product lineup, including Auvelity, Sunosi, and Symbravo. The company anticipates further revenue increases from new drug approvals and label expansions, such as Auvelity for Alzheimer's disease agitation and AXS-12 for cataplexy. With a vast addressable market and ongoing clinical progress, Axsome is poised for continued momentum and investor upside.
Axsome Therapeutics, Inc. (AXSM) Investor Outlook: Strong Buy Ratings and Promising 15.71% Potential Upside
Axsome Therapeutics (AXSM) is gaining investor attention with a $9.29 billion market capitalization and an innovative approach to CNS disorders. Despite not yet being profitable, the company shows significant revenue growth and a strong product pipeline, including Auvelity and Sunosi. Analysts are overwhelmingly positive, with 19 buy ratings and an average target price suggesting a 15.71% potential upside, making it an attractive prospect for growth-oriented investors.
Axsome Therapeutics (NASDAQ:AXSM) CEO Sells $6,015,296.00 in Stock
Axsome Therapeutics CEO Herriot Tabuteau sold 32,410 shares of AXSM stock for over $6 million on February 2nd, reducing his ownership by 81.76%. This sale is part of a series of insider dispositions totaling tens of millions of dollars since December. Despite the CEO's sales and negative EPS, AXSM trades near $185.88 with a $9.37 billion market cap and a consensus "Moderate Buy" rating.
Understanding Momentum Shifts in (AXSM)
The article analyzes Axsome Therapeutics Inc. (AXSM), indicating a near-term neutral sentiment contrasting with mid and long-term strength. It highlights a lack of clear price positioning signals and elevated downside risk due to the absence of additional long-term support. The analysis provides AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging.
J. Safra Sarasin Holding AG Has $1.08 Million Stake in Axsome Therapeutics, Inc. $AXSM
J. Safra Sarasin Holding AG significantly reduced its stake in Axsome Therapeutics ($AXSM) by 54.7% in Q3, now holding 8,897 shares valued at $1.08 million. Despite recent insider selling totaling $67.19 million, insiders still own 22.40% of the company. Wall Street analysts maintain a "Moderate Buy" consensus with a $206.22 price target, even as the stock trades near its 1-year high and reports strong 63% year-over-year revenue growth despite negative EPS.
Axsome Therapeutics (AXSM) Valuation Check As Phase 3 AXS 14 Fibromyalgia Trial Gets Underway
Axsome Therapeutics (AXSM) has begun its Phase 3 trial for AXS-14 in fibromyalgia, sparking renewed interest in its pipeline. Despite a significant recent share price rally, Simply Wall St's narrative suggests the stock is 10.5% undervalued with a fair value of $210.19, driven by its late-stage CNS disorder programs. However, this valuation depends on future revenue and profit margin shifts and carries risks related to reliance on existing products and ongoing net losses.
Axsome Therapeutics (AXSM) Valuation Check As Phase 3 AXS 14 Fibromyalgia Trial Gets Underway
Axsome Therapeutics has initiated a Phase 3 trial for AXS-14 in fibromyalgia, sparking renewed interest in its pipeline. Despite a strong recent share price performance, Simply Wall St's analysis suggests the stock is currently undervalued at $188.02, with a fair value estimated at $210.19, based on its diversified late-stage clinical programs. Investors are advised to consider potential risks such as reliance on existing products and ongoing net losses.
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
Axsome Therapeutics, Inc. (NASDAQ: AXSM) announced it will report its financial results for the fourth quarter and full year 2025 on Monday, February 23, 2026, before the opening of the U.S. financial markets. Management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update, with details for participation via dial-in or webcast available on their website. Axsome Therapeutics is a biopharmaceutical company focused on CNS disorders, with FDA-approved treatments and a pipeline of late-stage development programs.
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
Axsome Therapeutics, Inc. announced it will release its fourth quarter and full-year 2025 financial results on February 23, 2026, followed by a conference call at 8:00 a.m. ET to discuss the outcomes and provide a business update. The company specializes in central nervous system disorders with FDA-approved therapies and ongoing late-stage development programs. The announcement also highlights potential risks detailed in forward-looking statements.
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
Axsome Therapeutics, Inc. (NASDAQ: AXSM) will announce its financial results for the fourth quarter and full year 2025 on Monday, February 23, 2026, before market open. The company will host a conference call and webcast at 8:00 a.m. ET to discuss these results and provide a business update. Axsome Therapeutics is a biopharmaceutical company focused on central nervous system disorders with multiple FDA-approved treatments and late-stage development programs.
Axsome investors get Q4 and full-year 2025 results ahead of Feb. 23 call
Axsome Therapeutics (NASDAQ: AXSM) announced that it will report its fourth quarter and full year 2025 financial results on Monday, February 23, 2026, before U.S. market open. The company's management will host a conference call at 8:00 a.m. Eastern Time to discuss the results and provide a business update. Investors can participate via a live dial-in or webcast available on Axsome's website.
Universal Beteiligungs und Servicegesellschaft mbH Increases Position in Axsome Therapeutics, Inc. $AXSM
Universal Beteiligungs und Servicegesellschaft mbH has increased its stake in Axsome Therapeutics by 30.7%, now owning 67,902 shares valued at approximately $8.25 million. This increase comes despite significant insider selling in the last quarter, with Axsome's CFO and CEO reducing their holdings. While the company missed EPS expectations, its revenue grew by 63.2%, and Wall Street analysts largely maintain a positive "Moderate Buy" rating with a consensus price target of $203.17, citing potential upside from a possible Auvelity label expansion.
Cabot Wealth Management Inc. Buys Shares of 5,560 Axsome Therapeutics, Inc. $AXSM
Cabot Wealth Management Inc. initiated a new position in Axsome Therapeutics, purchasing 5,560 shares valued at approximately $675,000 during Q3. Despite significant insider selling over the past three months, analyst sentiment remains largely positive with a consensus "Moderate Buy" rating and a price target of $203.17. The company's stock has recently hit new 12-month highs following analyst upgrades and positive sentiment regarding potential label expansion for its depression drug, Auvelity.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Recommendation of "Moderate Buy" by Analysts
Axsome Therapeutics (NASDAQ:AXSM) has received a consensus "Moderate Buy" rating from analysts, with an average 1-year price target of $203.17. Several firms recently raised their price targets, and Piper Sandler anticipates a likely label expansion for Axsome's drug Auvelity by April 30. Despite strong revenue growth and optimism around clinical catalysts, the company missed quarterly EPS estimates and has seen significant insider selling, though insiders retain a substantial ownership stake.
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
Axsome Therapeutics, Inc. announced it will release its fourth quarter and full year 2025 financial results on February 23, 2026, before market opening, followed by a conference call at 8:00 a.m. ET. The call will discuss these results and provide a business update for the biopharmaceutical company focused on CNS disorders. Axsome's portfolio includes FDA-approved treatments and several late-stage development programs.
Pizzie, Axsome Therapeutics CFO, sells $2.25m in shares
Nick Pizzie, CFO of Axsome Therapeutics (NASDAQ:AXSM), sold 12,000 shares for $2.25 million on January 22, 2026, while also exercising options to acquire an equivalent number of shares. This transaction occurred as AXSM traded near its 52-week high, following an impressive 80% return over the past year. Analysts remain highly bullish on the company, which continues strategic initiatives such as a Phase 3 trial for AXS-14 and significant product revenue growth.
MoneyShow Top Picks 2026: Axsome Therapeutics Inc. (AXSM)
Axsome Therapeutics Inc. (AXSM) is highlighted as a top pick for 2026 due to its diverse pipeline, including three currently marketed drugs with significant sales growth and several others anticipated to receive FDA approval in 2026. The company is expected to achieve profitability in 2026, with strong sales growth projected for years to come. Despite potential near-term volatility, the stock shows a positive trajectory, especially with upcoming drug approvals.
Ari Maizel, chief commercial officer of Axsome, sells $1.38m in shares
Ari Maizel, Chief Commercial Officer of Axsome Therapeutics Inc (NASDAQ:AXSM), sold 7,500 shares worth $1.38 million on January 21, 2026, while also exercising options for 7,500 shares. The transactions were conducted under a pre-approved trading plan, as Axsome trades near its 52-week high with significant year-over-year growth in product revenue and positive analyst outlooks. The company also initiated a Phase 3 trial for AXS-14, targeting fibromyalgia management.
Axsome Therapeutics (NASDAQ:AXSM) CFO Sells $2,255,040.00 in Stock
Axsome Therapeutics' (NASDAQ:AXSM) CFO, Nick Pizzie, sold 12,000 shares worth $2,255,040 on January 22nd, reducing his stake by 21.98%. This comes as Axsome missed Q3 EPS estimates but saw significant revenue growth, remaining unprofitable. Analyst sentiment is largely positive with a "Moderate Buy" consensus and an average price target of $203.17, despite the insider selling and mixed financial results.
Axsome Therapeutics (AXSM) Is Up 7.4% After Advancing AXS-14 Into Phase 3 FORWARD Fibromyalgia Trial
Axsome Therapeutics (AXSM) saw its stock rise 7.4% after announcing the progression of AXS-14 into the Phase 3 FORWARD trial for fibromyalgia, with the first patient dosed in January 2026. This clinical advancement, coupled with strong preliminary 2025 product revenue guidance, highlights the company's progress in both its late-stage pipeline and commercial portfolio. The news suggests medium-term optionality for investors, though execution risk remains as Axsome aims to convert top-line growth into sustainable profitability across multiple development programs.
Piper Sandler Bullish on Axsome Therapeutics (AXSM) Ahead of Likely Auvelity Label Expansion by April 30
Piper Sandler maintains a bullish outlook on Axsome Therapeutics (AXSM), raising its price target to $223 due to the anticipated FDA label expansion of Auvelity for Alzheimer’s agitation by April 30, 2026. This optimism is reinforced by the drug's strong performance in the depression market and its patent exclusivity until 2039. Other firms like Baird and Wells Fargo have also increased their price targets for AXSM, citing impressive Q4 2025 sales and an increased probability of success for the ADA indication.
Axsome Therapeutics stock hits all-time high at 184.45 USD
Axsome Therapeutics Inc. reached an all-time high of $184.45, reflecting strong investor confidence and positive market sentiment, driven by a 92.82% stock value increase over the past year. Despite impressive revenue growth and gross profit margins, analysts do not expect profitability this year. Recent news includes strong Q4 2025 revenue projections and raised price targets from several analysts following positive commercial product sales and progress in clinical trials.
HC Wainwright Has Bullish Estimate for AXSM FY2026 Earnings
HC Wainwright has increased its FY2026 EPS estimate for Axsome Therapeutics (NASDAQ:AXSM) to $3.91, maintaining a "Buy" rating and a $260 price target. Despite the bullish outlook and a 4.1% rise in share price, the company remains unprofitable with a negative net margin, and corporate insiders have been net sellers, divesting over $63.55 million in shares recently. Institutional investors, however, hold a significant 81.5% stake in the company.
Axsome Therapeutics (AXSM) Valuation Check After Strong Recent Share Price Momentum
Axsome Therapeutics (AXSM) has seen strong share price momentum recently, with a 30-day return of 20.9% and a one-year return of 91.8%. The company's Price-to-Sales (P/S) ratio of 16.6x is above the broader US Pharmaceuticals industry average but below its peer group, suggesting a nuanced valuation. While the P/S ratio indicates the stock is "about right," a discounted cash flow (DCF) model suggests significant undervaluation, presenting a question for investors about market caution versus optimistic assumptions.
Axsome Therapeutics stock hits all-time high at 184.45 USD By Investing.com
Axsome Therapeutics (NASDAQ: AXSM) stock reached a new all-time high of $184.45, reflecting strong investor confidence and a significant 92.82% increase in value over the past year. Analysts are optimistic about the company's future, with price target raises from H.C. Wainwright, Baird, and Piper Sandler, and continued progress in its product pipeline, including positive revenue growth and the advancement of its Phase 3 trial for AXS-14.
Axsome Therapeutics (NASDAQ:AXSM) Hits New 1-Year High on Analyst Upgrade
Axsome Therapeutics (NASDAQ:AXSM) reached a new 52-week high following an analyst upgrade from HC Wainwright, which raised its price target from $200 to $260. Despite notable insider selling, the consensus analyst rating remains a "Moderate Buy" with an average target price of $202. The company, a clinical-stage biopharmaceutical firm focusing on CNS disorders, reported Q3 earnings that missed consensus estimates but showed a significant year-over-year revenue increase.
Axsome Therapeutics stock hits all-time high at 184.45 USD By Investing.com
Axsome Therapeutics' stock reached an all-time high of $184.45, reflecting strong investor confidence and significant growth. This growth is backed by promising product pipeline developments, strategic advancements, and strong revenue growth, though analysts do not expect profitability this year. Recent positive news includes robust Q4 2025 product revenue and increased price targets from multiple analysts.
